<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Biomol Struct Dyn</journal-id><journal-id journal-id-type="iso-abbrev">J. Biomol. Struct. Dyn</journal-id><journal-title-group><journal-title>Journal of Biomolecular Structure &#x00026; Dynamics</journal-title></journal-title-group><issn pub-type="ppub">0739-1102</issn><issn pub-type="epub">1538-0254</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7441762</article-id><article-id pub-id-type="doi">10.1080/07391102.2020.1794970</article-id><article-id pub-id-type="publisher-id">1794970</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Express Communication</subject></subj-group></article-categories><title-group><article-title>Natural derivatives with dual binding potential against SARS-CoV-2 main protease and human ACE2 possess low oral bioavailability: a brief computational analysis</article-title><alt-title alt-title-type="left-running-head">P. Sharma and A. Shanavas</alt-title><alt-title alt-title-type="right-running-head">Journal of Biomolecular Structure and Dynamics</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Priyanka</given-names></name><xref ref-type="aff" rid="AF0001"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7221-7477</contrib-id><name><surname>Shanavas</surname><given-names>Asifkhan</given-names></name><xref ref-type="corresp" rid="AN0001"/><xref ref-type="aff" rid="AF0001"/></contrib><aff id="AF0001"><institution>Inorganic &#x00026; Organic Nanomedicine Lab, Institute of Nano Science and Technology</institution>, <city>Mohali</city>, <state>Punjab</state>, <country>India</country></aff></contrib-group><author-notes><corresp id="AN0001"><bold>CONTACT</bold> Asifkhan Shanavas <email>asifkhan@inst.ac.in</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>21</day><month>7</month><year>2020</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2020</year></pub-date><fpage seq="1">1</fpage><lpage>12</lpage><permissions><copyright-statement>&#x000a9; 2020 Informa UK Limited, trading as Taylor &#x00026; Francis Group</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Informa UK Limited, trading as Taylor &#x00026; Francis Group</copyright-holder><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="TBSD_0_1794970.pdf"/><abstract><title>Abstract</title><p>The world is witnessing severe health meltdown due to COVID-19. Generic antiviral drug remdesivir has been found to reduce time to clinical recovery but with insignificant clinical benefits and the antimalarial drug, hydroxychloroquine has been red flagged by USFDA for use as a prophylactic measure due to its cardiotoxicity. There is an acute requirement for a drug candidate that has significant clinical benefit with minimal to no side effects. With restricted access to wet laboratory techniques, an alternative approach is to engage in computational screening of lead molecules that could inhibit SARS-CoV-2 at different stages of its infectious cycle. Several <italic>in silico</italic> studies on natural derivatives, especially that present in daily refreshments (tea and fruit juices), staple food (black rice, red onions, soy beans etc) and traditional medicines (extracts of herbs, leaves and flowers) have been identified as potential drug candidates that bind efficiently with the key viral proteins. However, oral bioavailability of these nutriments is considerably low due to either poor permeability or loss of structure and function due to digestion in the gastrointestinal tract. Here we discuss few natural secondary metabolites (Delphinidin 3,5-diglucoside, Scutellarein 7-glucoside, Avicularin and 3,5-Di-O-galloylshikimic acid) that showed encouraging binding affinity against coronavirus main protease (M<sup>pro</sup>) and human ACE2 receptor with MM-GBSA energies up to &#x02212;74.0&#x02009;Kcal/mol and &#x02212;79.5&#x02009;Kcal/mol, respectively. However, their Abbott bioavailability score (ABS) of 0.11 or 0.17 predicts poor oral bioavailability. This study could trigger interest to engineer potential natural products in managing present or future pandemics.</p><p>Communicated by Ramaswamy H. Sarma</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Natural products</kwd><kwd>COVID</kwd><kwd>SARS-CoV-2</kwd><kwd>ACE2</kwd><kwd>bioavailability</kwd></kwd-group><counts><fig-count count="6"/><table-count count="1"/><page-count count="12"/><word-count count="6987"/></counts></article-meta></front><body><sec sec-type="intro" id="S0001" disp-level="1"><title>Introduction</title><p>Novel SARS-CoV2 is a pathogenic strain of coronavirus that is raising major concerns over the public health around the world. Coronaviruses are spherical enveloped viruses with positive sense single stranded RNA genome having a place in the Coronaviridae family and they cause respiratory tract infections in humans, animals and birds. SARS-like CoVs isolated from bats have 95% genome sequence identity with human SARS-CoVs, allowing them to directly infect humans without any requirement for an intermediate host (Hu et&#x000a0;al., <xref rid="CIT0019" ref-type="bibr">2018</xref>). The genome of SARS coronaviruses comprise 5&#x02032; open reading frame ORF (1a and 1b coding region, S region encodes spike glycoprotein, E region encodes enveloped protein, M region encodes membrane protein, N region encodes nucleocapsid protein, six accessory proteins encoded by ORF 3a, ORF 6, ORF 7a, ORF 7b, ORF 8 and 3&#x02032; terminal non-coding region) (Rota et&#x000a0;al., <xref rid="CIT0038" ref-type="bibr">2003</xref>). The trimeric S glycoprotein contains two S1 and S2 subunits for interaction with host cell receptor and for fusion with host cell, respectively (Wu et&#x000a0;al., <xref rid="CIT0047" ref-type="bibr">2020</xref>). Fan Wu et&#x000a0;al. revealed that the receptor-binding domain (RBD) of COVID-19 spike protein is fundamentally the same as that of SARS-CoVs (73.8&#x02013;74.9% amino acid character) and SARS-like CoVs, including strains Rs4874, Rs7327 and Rs4231 (75.9&#x02013;76.9% amino acid) (Wu et&#x000a0;al., <xref rid="CIT0047" ref-type="bibr">2020</xref>; Yuan et&#x000a0;al., <xref rid="CIT0049" ref-type="bibr">2017</xref>). Peng Zhou et&#x000a0;al. confirmed that SARS-CoV-2 uses human ACE2 receptor for cell entry (Q. Wang et&#x000a0;al., <xref rid="CIT0045" ref-type="bibr">2020</xref>; P. Zhou et&#x000a0;al., <xref rid="CIT0052" ref-type="bibr">2020</xref>) and this receptor can turn out to be a potential target to block the attachment of SARS-CoV-2 spike protein (Zhang et&#x000a0;al., <xref rid="CIT0051" ref-type="bibr">2020</xref>). Among several viral proteins, the main protease of SARS-Cov2 (M<sup>pro</sup>) is more potent target due to its vital role in the virus replication and transcription inside the host cells (Jin et&#x000a0;al., <xref rid="CIT0021" ref-type="bibr">2020</xref>). As the novel coronavirus (SARS-CoV-2) have sequence homology with SARS and MERS thus the existing antiviral drugs seem effective against SARS-CoV-2. Remdesivir, a nucleotide analogue inhibitor of RdRp and antimalarial drug chloroquine effectively inhibited the SARS-CoV-2 infection <italic>in&#x000a0;vitro</italic> (M. Wang et&#x000a0;al., <xref rid="CIT0045" ref-type="bibr">2020</xref>). Hydroxychloroquine, an analogue of chloroquine is also a drug candidate after <italic>in&#x000a0;vitro</italic> (Yao et&#x000a0;al., <xref rid="CIT0048" ref-type="bibr">2020</xref>) and clinical investigations (Gautret et&#x000a0;al. 2020). Considering the increase in fatality, there is an urgent requirement to channeled approved drugs and natural active compounds towards fighting the pandemic (Y. Zhou et&#x000a0;al., <xref rid="CIT0052" ref-type="bibr">2020</xref>). This has led to several computational studies that screened hundreds of small molecules for their binding to key proteins such as spike glycoprotein, envelop protein, membrane protein and nucleocapsid protein (Das et al., <xref rid="CIT0007" ref-type="bibr">2020</xref>; Islam et al., <xref rid="CIT0020" ref-type="bibr">2020</xref>; Farag et al., <xref rid="CIT0001" ref-type="bibr">2020</xref>; Micael et al., <xref rid="CIT0031" ref-type="bibr">2020</xref>; Pandit et al., <xref rid="CIT0034" ref-type="bibr">2020</xref>; Ubani et al., <xref rid="CIT0043" ref-type="bibr">2020</xref>; Tallei et al., <xref rid="CIT0041" ref-type="bibr">2020</xref>; Romulo et al., <xref rid="CIT0038" ref-type="bibr">2020</xref>; Liu et al., <xref rid="CIT0024" ref-type="bibr">2020</xref>). As natural product repository has overwhelming number of leads that may act as both blocker of receptor mediated host cell uptake of the viral particles and inhibitor of the viral replication. In this direction, we have selected two target proteins (viral protein, M<sup>pro</sup> and host receptor protein, ACE2) and performed docking studies to screen potential natural products. Further, <italic>in silico</italic> ADME (Absorption, Distribution, Metabolism, Excretion) analysis has been performed to understand their suitability as a drug candidate. While the top leads, Delphinidin 3,5-diglucoside, Scutellarein 7-glucoside, Avicularin and 3,5-Di-O-galloylshikimic acid show optimal binding at the active site of both SARS-CoV-2 M<sup>pro</sup> and ACE2, ADME calculations show that all these molecules have low bioavailability.</p></sec><sec sec-type="materials" id="S0002" disp-level="1"><title>Material and methods</title><sec id="S0002-S2001" disp-level="2"><title>Target selection</title><p>We selected viral and host targets, SARS CoV-2 main protease (Mpro) and ACE2, respectively to identify effective leads. Mpro is a homodimer with two protomers, each containing three domains (I, II and III) and a CYS-HIS catalytic dyad inside the cleft between domain I and II. This cleft has four subsites (S1, S1&#x02032;, S2 and S4) that remain conserved in all coronavirus Mpro. The other target is a host protein, ACE2 (angiotensin-converting enzyme-related carboxypeptidase) which is having HEXXH-E zinc-binding consensus sequence. Extracellular region of ACE2 consist of two domains (I and II), a zinc metallopeptidase (residues 19&#x02013;611) and C terminus (residues 612&#x02013;740). Zinc metallopeptidase further have two domains in which catalytic site for ACE2 inhibitors is present. Along with the presence of residues coordinating with the zinc the catalytic site also have two subsites S1 and S1&#x02032; defined by specific residues which occupies major portion providing substrate binding specificity (Towler et&#x000a0;al., <xref rid="CIT0042" ref-type="bibr">2004</xref>).</p></sec><sec id="S0002-S2002" disp-level="2"><title>Molecular docking and natural products screening</title><p>Molecular docking was performed, using glide package of Schr&#x000f6;dinger chemical simulation software (Schr&#x000f6;dinger, LLC, and New York, NY). The crystal structure of SARS-Cov-2 M<sup>pro</sup> and ACE2 was sourced from PDB data bank (PDB-ID: 6lu7 (Jin et&#x000a0;al., <xref rid="CIT0021" ref-type="bibr">2020</xref>), 1R4L (Towler et&#x000a0;al., <xref rid="CIT0042" ref-type="bibr">2004</xref>)). The protein preparation wizard was utilized to preprocess the crystal structure which includes removal of water molecules present beyond 5&#x02009;&#x000c5;, addition of right bond order, addition of H-atoms and optimization of hydroxyl and amino groups. Restrained minimization was performed using OPLS3 force field until the average root mean square deviation of the non-hydrogen atoms reached 0.3&#x02009;&#x000c5;. The receptor grid generation module was employed to generate grid for M<sup>pro</sup> and ACE2 co-crystallized with its inhibitors, N3 and MLN4760, respectively. Position of N3 and MLN-4760 was set as the primary active site for the docking of selected ligands. The size of protein grid was optimized by re-docking of co-crystallized ligand within RMSD value &#x0003c; 2&#x02009;&#x000c5;. Up to 55 molecules (Source: PUBchem) were imported to the LigPrep module of Schr&#x000f6;dinger software package to generate possible ionization states at the pH range 7&#x02009;&#x000b1;&#x02009;2 using Epik. Up to 60 conformers were generated for single ligand and chirality was determined from the 3D structure. The generated conformers of all the screened ligands were docked to the M<sup>pro</sup> using extra precision mode.</p></sec><sec id="S0002-S2003" disp-level="2"><title>MM-GBSA dG binding energy calculations</title><p>On the basis of binding interaction energies ligand-protein complexes were re-scored by using MM-GB/SA (molecular mechanics energies combined with generalized born and surface area) module of Schr&#x000f6;dinger software to enhance the binding affinity predictions.</p></sec><sec id="S0002-S2004" disp-level="2"><title>ADME parameters calculations</title><p>It is vital to explore the pharmacokinetic profile of a molecule to be eligible as an active drug in clinical trial. The druggability of screened molecules were investigated for ADME properties using Swiss ADME software (Daina et&#x000a0;al., <xref rid="CIT0006" ref-type="bibr">2017</xref>). Three pharmacokinetic parameters (Lipophilicity, solubility and bioavailability) were considered for the purpose of handling and formulation. Lipophilicity (Log P) calculations were based on XLOGP3 model (Cheng et&#x000a0;al., <xref rid="CIT0004" ref-type="bibr">2007</xref>) and solubility calculation was based on ESOL model (Delaney, <xref rid="CIT0008" ref-type="bibr">2004</xref>), while bioavailability scores were based on the method developed by Martin (<xref rid="CIT0027" ref-type="bibr">2005</xref>).</p></sec></sec><sec sec-type="results" id="S0003" disp-level="1"><title>Results and discussion</title><p>SARS CoV-2 main protease (M<sup>pro</sup>) and ACE2 were used as target to identify effective leads. M<sup>pro</sup> processes polyproteins into 16 non-structural proteins (NSPs), which further generates subgenomic RNAs encoding for four main structural proteins (envelope (E), membrane (M), spike (S) and nucleocapsid (N) proteins) and other additional proteins (Coleman et&#x000a0;al., <xref rid="CIT0005" ref-type="bibr">2014</xref>; Lu et&#x000a0;al., <xref rid="CIT0025" ref-type="bibr">2020</xref>; Roh, <xref rid="CIT0038" ref-type="bibr">2012</xref>). In the S1 subsite of M<sup>pro</sup>, GLN is vital for high cleavage efficiency and is specific to this particular protease. There is no known M<sup>pro</sup> human homolog with similar cleavage site making it an interesting antiviral target with lower probability of inhibitor toxicity. While human ACE2 belongs to the category of type I integral membrane protein having 805 amino acids. Despite its role in making a pathway for SARS-CoV2 (Q. Wang et&#x000a0;al., <xref rid="CIT0045" ref-type="bibr">2020</xref>), ACE2 prevents lung injuries, resulting in worsening of pathological condition (Zhang et&#x000a0;al., <xref rid="CIT0051" ref-type="bibr">2020</xref>).</p><p>The catalytic sub domain of human ACE2 in presence of inhibitor undergoes hinge bending movement causing the deep cleft of the subdomain I of enzyme to wrap the inhibitor. This closing of subdomain I around inhibitor changes the conformation of the whole receptor making it less susceptible to interact with SARS-CoV2 receptor binding domain. In the free form zinc makes coordination bonds with three residues (HIS<sup>374</sup>, HIS<sup>378</sup> and GLU<sup>402</sup>) and a water molecule (Towler et&#x000a0;al., <xref rid="CIT0042" ref-type="bibr">2004</xref>). The leads are explored under two key categories (a) drug candidates undergoing clinical evaluation and (b) natural products (Arts et&#x000a0;al., <xref rid="CIT0002" ref-type="bibr">2004</xref>; McGhie &#x00026; Walton, <xref rid="CIT0029" ref-type="bibr">2007</xref>; Okonogi et&#x000a0;al., <xref rid="CIT0033" ref-type="bibr">2016</xref>; Paul et&#x000a0;al., <xref rid="CIT0035" ref-type="bibr">2018</xref>; Stenlid, <xref rid="CIT0040" ref-type="bibr">1976</xref>; Yuldashev, <xref rid="CIT0050" ref-type="bibr">2002</xref>) (<xref rid="t0001" ref-type="table">Table 1</xref>). Glide (Friesner et&#x000a0;al., <xref rid="CIT0013" ref-type="bibr">2004</xref>) Extra Precision (XP) approach was used for screening of candidates followed by calculation of MM-GBSA energies to increase accuracy, and reliability of the docking process. The SARS-CoV2 M<sup>pro</sup> crystal structure plays an important role in identifying lead drugs through molecular simulation studies. The crystal structure sourced from protein databank has co-crystallized ligand N3, a michael acceptor that act as an irreversible inhibitor (Jin et&#x000a0;al., <xref rid="CIT0021" ref-type="bibr">2020</xref>). To validate the methods utilized in this work, N3 was re-docked to its active site in M<sup>pro</sup> (RMSD value &#x0003c; 2&#x02009;&#x000c5;). The docking yielded similar binding interactions as reported by Zhenming et&#x000a0;al. and the MM-GBSA binding energy for N3 was calculated to be &#x02212;80&#x02009;Kcal/mol. The lactam of N3 embeds into the S1 subsite and forms a hydrogen bond with H<sup>163</sup> as reported earlier. Also, N3 forms multiple hydrogen bonds with the residues in the substrate-binding pocket. The docking pose is presented in <xref ref-type="fig" rid="F0001">Figure 1(i)</xref>. On the other hand the crystal structure of human ACE2 (PDB ID: 1R4l) <xref ref-type="fig" rid="F0002">Figure 2(i)</xref> bound with its inhibitor (MLN-4760) was also validated by re-docking. The residues involved in the binding site showed similar interaction as reported by Towler et&#x000a0;al. with the docking score of &#x02212;10.74&#x02009;Kcal/mol and MM-GBSA score of &#x02212;51.79&#x02009;Kcal/mol. ACE2 behaves differently with or without the inhibitor. In the presence of its inhibitor subdomain I of zinc matallopeptidase undergo conformational change which could prevents the binding of SARS-CoV2 to its surface.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Docked pose and binding interactions of N3 (i), GS-441524 (ii) and Hydroxychloroquine (iii) with SARS-Cov-2 M<sup>pro</sup>.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1794970_F0001_C"/></fig><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Docked pose and binding interactions of MLN-4765 (i), GS-441524 (ii) and Hydroxychloroquine (iii) with ACE2.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1794970_F0002_C"/></fig><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Docking scores of N3/MLN-4760 (1), drug candidates undergoing clinical trials (2a/b and 3) and potential natural compounds (4&#x02013;7) against SARS-CoV2 M<sup>pro</sup> (6LU7) and ACE2 (1R4L) and their ADME properties.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">S.no</th><th align="center">Leads</th><th align="center">Docking score (Kcal/mol) 6LU7/1R4L</th><th colspan="2" align="center">Lipophilicity (Log P)</th><th align="center">Solubility (Log S)</th><th align="center">Bioavailability score</th><th align="center">MM-GBSA dG bind (Kcal/mol)</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>1.</bold></td><td align="left">N3/MLN-4765 (Co-crystallized inhibitors of M<sup>pro</sup>/ACE2)</td><td align="center">&#x02212;8.93/&#x02212;10.74</td><td colspan="2" align="center">2.22</td><td align="center">&#x02212;3.77</td><td align="center">0.17<xref ref-type="table-fn" rid="TF1">*</xref></td><td align="center">&#x02212;80.27/&#x02212;51.79</td></tr><tr><td align="left"><bold>2a.</bold></td><td align="left">Remdesivir</td><td align="center">&#x02212;8.21/ &#x02212;6.42</td><td colspan="2" align="center">1.91</td><td align="center">&#x02212;4.12</td><td align="center">0.17<xref ref-type="table-fn" rid="TF1">*</xref></td><td align="center">&#x02212;71.68/ &#x02212;51.52</td></tr><tr><td align="left"><bold>2b.</bold></td><td align="left">GS-441524 (Active metabolite of Remdesivir)</td><td align="center">&#x02212;6.24/&#x02212;5.65</td><td colspan="2" align="center">&#x02212;1.41</td><td align="center">&#x02212;0.94</td><td align="center">0.55<xref ref-type="table-fn" rid="TF2">**</xref></td><td align="center">&#x02212;46.51/&#x02212;40.48</td></tr><tr><td align="left"><bold>3.</bold></td><td align="left">Hydroxy-chloroquine</td><td align="center">&#x02212;7.11/&#x02212;7.6</td><td colspan="2" align="center">3.58</td><td align="center">&#x02212;3.91</td><td align="center">0.55<xref ref-type="table-fn" rid="TF2">**</xref></td><td align="center">&#x02212;67.53/ &#x02212;59.03</td></tr><tr><td align="left"><bold>4.&#x000a0;</bold></td><td align="left">Delphinidin 3,5-diglucoside</td><td align="center">&#x02212;12.2/&#x02212;13.6</td><td colspan="2" align="center">&#x02212;2.02</td><td align="center">&#x02212;2.27</td><td align="center">0.17<xref ref-type="table-fn" rid="TF1">*</xref></td><td align="center">&#x02212;74.0/&#x02212;79.5</td></tr><tr><td align="left"><bold>5.</bold></td><td align="left">Scutellarein 7-glucoside</td><td align="center">&#x02212;9.3/ &#x02212;10.6</td><td colspan="2" align="center">0.51</td><td align="center">&#x02212;3.05</td><td align="center">0.17<xref ref-type="table-fn" rid="TF1">*</xref></td><td align="center">&#x02212;68.55/ &#x02212;59.1</td></tr><tr><td align="left"><bold>6.</bold></td><td align="left">Avicularin</td><td align="center">&#x02212;9.6/ &#x02212;8.0</td><td colspan="2" align="center">0.98</td><td align="center">&#x02212;3.27</td><td align="center">0.17<xref ref-type="table-fn" rid="TF1">*</xref></td><td align="center">&#x02212;66.6/ &#x02212;44.50</td></tr><tr><td align="left"><bold>7.</bold></td><td align="left">3,5-Di-O-galloylshikimic acid</td><td align="center">&#x02212;10.3/ &#x02212;11.2</td><td colspan="2" align="center">0.61</td><td align="center">&#x02212;2.99</td><td align="center">0.11<xref ref-type="table-fn" rid="TF1">*</xref></td><td align="center">&#x02212;35.1/ &#x02212;51.7</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><label>*</label><p>Lipinski&#x02019;s rule &#x02013; 2 violations.</p></fn><fn id="TF2"><label>**</label><p>Passes Lipinski&#x02019;s rule.</p></fn></table-wrap-foot></table-wrap><p>Further we attempted to dock GS-441524 (active form of remdesivir) and hydrochloroquine, which are being repurposed for treating COVID-19. The rational for including these molecules is that their principle inhibitory mechanism takes place inside the host cell where viral replication unfolds. The possibility for these molecules to bind to off&#x02013;target proteins that are of viral or host origin cannot be ruled out. Recently FDA has issued an Emergency Use Authorization (EUA) for remdesivir to be included in treatment protocol of hospitalized SARS-CoV-2 infected patients (Rhoades, <xref rid="CIT0037" ref-type="bibr">2020</xref>).</p><p>Remdesivir is a prodrug of adenosine triphosphate (ATP) analog, GS-441524 that interferes with the action of viral RNA-dependent RNA polymerase towards controlling viral RNA production. From the present study, the estimated docking scores and MM-GBSA bind energies for GS-441524 are &#x02212;6.24&#x02009;Kcal/mol and &#x02212;46.51&#x02009;Kcal/mol for Mpro and &#x02212;5.65&#x02009;Kcal/mol and &#x02212;40.48&#x02009;Kcal/mol for ACE2, respectively. For SARS-CoV2 M<sup>pro</sup> the docked poses of GS-441524 shows the hydroxyl groups of oxolan ring are inserted inside the S1 subunit by multiple hydrogen bonds with the CYS<sup>145</sup> and ASN<sup>142</sup>. The nitrogen of the nitrile group was found to form a hydrogen bond with the GLU<sup>166</sup> of the side chain of S1 subunit. However for ACE2 multiple hydrogen bonds were formed by hydroxyl groups of the oxolane ring with PRO<sup>346</sup>, ARG<sup>273</sup> of S1 subsite, and ARG<sup>518</sup> of the side chain. The oxygen of the oxolane ring was found forming hydrogen bond with the THR371 residue of the side chain. The free amine group interacts with the ASP<sup>367</sup> residue of the S1&#x02032; subsite through hydrogen bonding. Non-specific binding to M<sup>pro</sup> might be also contribute to the overall CoV inhibitory potential of the drug, which has shown encouraging results in terms of reduced time to clinical recovery but with insignificant clinical benefits in COVID-19 patients. However, further <italic>in&#x000a0;vitro</italic> target-ligand interaction studies are required to assess concentration dependence of its inhibitory effect via M<sup>pro</sup> binding. Similar to remdesivir, Hydroxychloroqine has also been assigned for EUA from FDA (<xref rid="CIT0011" ref-type="bibr">2020</xref>) to treat hospitalized, severely ill SARS-CoV2 infected patients.</p><p>The MM-GBSA binding energy for HCQ with M<sup>pro</sup> and ACE2 was found to be &#x02212;67.53&#x02009;Kcal/mol and &#x02212;59.03&#x02009;Kcal/mol. In the M<sup>pro</sup> catalytic site it forms &#x003c0;-&#x003c0; stacking interaction between quinolin and HIE<sup>41</sup> of the hydrophobic S2 subunit. The hydrogen of the two amine groups was showing interaction with the GLN<sup>189</sup> and CYS<sup>145</sup> through hydrogen bond and non-covalent ionic interaction (salt bridge). The hydroxyl group of the alkyl chain was found to interact through hydrogen bond with GLY<sup>143</sup> residue of the S1 subunit. While this drug shows good binding to M<sup>pro</sup> catalytic site, it is also labeled for possible cardiac injury (FDA, <xref rid="CIT0011" ref-type="bibr">2020</xref>). While in the catalytic site of ACE2 the free hydroxyl group of alkyl chain and the hydrogen of tertiary amine group interact with the side chain residue ASP<sup>367</sup> through hydrogen bonds and one non-covalent ionic interaction was also formed between ASP<sup>367</sup> and hydrogen of tertiary amine group. The side chain residue HIE<sup>345</sup> was found to interact through couple of &#x003c0;-&#x003c0; stacking interaction with the two rings of quinolin nucleus. The 2D and 3D docking pose of both remdesivir and hydroxychloroquine in SARS-CoV-2 M<sup>pro</sup> and ACE2 is presented in <xref ref-type="fig" rid="F0001">Figure 1(ii) and (iii)</xref> and <xref ref-type="fig" rid="F0002">Figure 2 (ii) and (iii)</xref>.</p><p>Among the 30 natural secondary metabolites screened, the top four leads exhibiting highest binding affinity were re-scored for their MM-GB/SA dG bind energies and predict their docking poses (Guimar&#x000e3;es &#x00026; Cardozo, <xref rid="CIT0017" ref-type="bibr">2008</xref>). All these four natural secondary metabolites were found to fit perfectly at the active site pockets of SARS-CoV-2 M<sup>pro</sup> and human ACE2. By analysis of the interactions it can be inferred that the active site of M<sup>pro</sup> is polar in nature and shows good binding energies with ligands having polar functional groups. All the top four leads are presented in <xref rid="t0001" ref-type="table">Table 1</xref> with corresponding docking scores, MM-GB/SA dG bind energies, and pharmacokinetic descriptors for both the targets. For SARS-CoV-2 M<sup>pro</sup>, similar to N3, the screened leads also engaged through multiple H-bond with the residues present in the cleft between domain I and II of M<sup>pro</sup> of SARS-CoV-2. The key residues involved in the binding interaction are GLN<sup>166</sup>, HIS<sup>163</sup>, THR<sup>190</sup>, CYS<sup>145</sup>, GLN<sup>189</sup> of main chain bonded through H-bonding and H41 of the hydrophobic pocket through &#x003c0; stacking interaction. Delphinidin 3,5-diglucoside is an anthocyanin mainly found in high concentration in pomegranates. It is a phenolic compound formed of anthocyanidin unit which is linked to carbohydrate moiety with O-glycoside at the C5-position. There are few reports on the therapeutic potential of this anthocyanin as an anticancer agent against colon and fibrosarcoma cancer. One of them reported that it significantly inhibited the HCT 116 and HT-29 human colon cancer cells (Mazewski et&#x000a0;al., <xref rid="CIT0028" ref-type="bibr">2019</xref>). In another study, delphinidin-3,5-glucoside showed cytotoxicity in combination with other anthocyanins (gallic acid, delphinidin and pelargonidin3-glucosides) (Filipiak et&#x000a0;al., <xref rid="CIT0012" ref-type="bibr">2014</xref>).</p><p>Present <italic>in silico</italic> analysis showed its highest binding affinity against for both the targets, M<sup>pro</sup> and ACE2. The estimated docking scores were &#x02212;12.2&#x02009;Kcal/mol for M<sup>pro</sup> and &#x02212;13.6&#x02009;Kcal/mol for ACE2 and MM-GBSA dG binding energies came out be &#x02212;74&#x02009;Kcal/mol and &#x02212;79.47&#x02009;Kcal/mol, respectively, which are lowest among all the screened ligands for both the targets. The 2D and 3D generated docking poses in M<sup>pro</sup> (<xref ref-type="fig" rid="F0002">Figure 2(i)</xref>) shows that the hydroxyl groups of the glycone participate in H-bond interaction with GLU<sup>166</sup> and ASN<sup>142</sup> of the main chain, and with LEU<sup>141</sup> of S1 subunit. The hydroxyl groups of benzene ring interact with CYS<sup>145</sup> of the catalytic site and HIS<sup>164</sup> of the S2 subunit through H-bond. Docking results also exposed the &#x003c0;-&#x003c0; interaction between the benzene ring and the HIE41 of the hydrophobic cavity of S2 subunit. The hydroxyl group of flavylium nucleus found to be interacting with the THR<sup>190</sup> of S4 subunit. On the contrary 2D and 3D refined poses of delphinidin-3,5-glucoside (<xref ref-type="fig" rid="F0003">Figure 3(i)</xref>) in the catalytic site of ACE2 flag up pi-cation interaction between the rings of flavylium nucleus and the side chain residues ARG<sup>273</sup> and HIE<sup>345</sup> of the catalytic site. Flavylium rings were also showing &#x003c0;-&#x003c0; interaction with the residues HIE<sup>345</sup> and HIS<sup>374</sup>and its hydroxyl was bonded through hydrogen bond to the GLU<sup>375</sup>. In addition to this the hydroxyls of the sugar moiety were found to have multiple hydrogen bond interaction with GLU406, THR371, ASH368, and ASP367. Likewise hydroxyls of the phenyl ring were bonded to TYR<sup>127</sup> with multiple hydrogen bonds.</p><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Docked pose and binding interactions of Delphinidin 3, 5-diglucoside (i), Scutellarein 7-glucoside (ii), Avicularin (iii) and 3,5-Di-O-galloylshikimic acid (iv) with SARS-Cov-2 M<sup>pro</sup>.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1794970_F0003_C"/></fig><p>The second lead compound is a flavonoid glycoside, Scutellarein 7-glucoside isolated from plants like <italic>Verbena officinalis L</italic> (Rehecho et&#x000a0;al., <xref rid="CIT0036" ref-type="bibr">2011</xref>), <italic>Buddleja madagascariensis Lam</italic> (Emam et al., <xref rid="CIT0010" ref-type="bibr">1998</xref>), <italic>Plantago asiatica L</italic>, <italic>Scutellaria immaculate</italic> (Yuldashev, <xref rid="CIT0050" ref-type="bibr">2002</xref>), <italic>Plantago asiatica L</italic> and <italic>Polygonum odoratum</italic> (Okonogi et&#x000a0;al., <xref rid="CIT0033" ref-type="bibr">2016</xref>). Biologically scutellarein 7-glucoside shows anti-inflammatory activity by decreasing the IL-6 and TNF-&#x003b1; production as reported by Okonogi et&#x000a0;al. (<xref rid="CIT0033" ref-type="bibr">2016</xref>). Another study reported by Goran et&#x000a0;al., shows its certain inhibitory activity against indole-3-acetic acid oxidase there by inhibiting ATP formation inside the plant mitochondria (Stenlid, <xref rid="CIT0040" ref-type="bibr">1976</xref>). In addition to these properties Rehecho et&#x000a0;al. (<xref rid="CIT0036" ref-type="bibr">2011</xref>) reported that it also shows free radical scavenging activity. The binding affinity docking scores of Scutellarein 7-glucoside against M<sup>pro</sup> and ACE2 are &#x02212;9.3&#x02009;Kcal/mol and &#x02212;10.6&#x02009;Kcal/mol. The MM-GBSA dG binding energies are &#x02212;68.55&#x02009;Kcal/mol and &#x02212;59.1&#x02009;Kcal/mol. In M<sup>pro</sup> all the hydroxyl groups of sugar moiety are involved in H-bonding with the CYS<sup>145</sup>, His<sup>163</sup> and GLU<sup>166</sup> which are the main residues of the catalytic site. Moreover hydroxyl group of phenyl ring also interacts with the GLN<sup>192</sup> residue of S4 subunit through hydrogen bonding that further secures scutellarein 7-glucoside binding to M<sup>pro</sup> (<xref ref-type="fig" rid="F0003">Figure 3(ii)</xref>). While in case of the ACE2 enzyme the hydroxyls of the sugar moiety were locking the Scutellarein 7-glucoside by forming multiple hydrogen bonds with GLU<sup>375</sup>, HIE<sup>345</sup> and HIE<sup>505</sup>. The phenyl ring was shown to make &#x003c0;-&#x003c0; stacking interaction with the phenyl ring of HIE<sup>345</sup>. The carbonyl oxygen and hydroxyl group of chromone nucleus were displaying hydrogen bond interaction with the THR<sup>371</sup> and ASH<sup>368</sup> (<xref ref-type="fig" rid="F0004">Figure 4(ii)</xref>).</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Docked pose and binding interactions of Delphinidin 3, 5-diglucoside (i), Scutellarein 7-glucoside (ii), Avicularin (iii) and 3,5-Di-O-galloylshikimic acid (iv) with ACE2.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1794970_F0004_C"/></fig><p>Avicularin is a flavonoid isolated from <italic>Polygonum aviculare, Rhododendron aureum and Taxillus kaempferi</italic> (Fukunaga et&#x000a0;al., <xref rid="CIT0015" ref-type="bibr">1989</xref>; Zhang et al., <xref rid="CIT0100" ref-type="bibr">1989</xref>). A derivative of quercetin, it possesses biological properties including anti-cancer, anti-inflammatory, anti-oxidant, anti-allergic properties. Van Anh Vo et&#x000a0;al., demonstrated the anti-inflammatory activity of avicularin by LPS-induced suppression of ERK signaling pathway in RAW 264.7 macrophage cells (Determination of Avicularin in Polygonum Aviculare L. by Square Wave Polarography. - PubMed - NCBI, n.d.). Avicularin elevated the sensitivity of cisplatin in drug resistant gastric cancer cells in <italic>in&#x000a0;vitro</italic> and <italic>in&#x000a0;vivo</italic> studies by enhancing the Bax and Bak expressions (Guo et&#x000a0;al., <xref rid="CIT0018" ref-type="bibr">2018</xref>). In another study, avicularin suppressed the intracellular accumulation of lipids by suppressing C/EBP&#x003b1;-mediated activation of GLUT4 expression in 3T3-L1 cells (Fujimori &#x00026; Shibano, <xref rid="CIT0014" ref-type="bibr">2013</xref>). Present computational analysis showed that it has good affinity to M<sup>pro</sup> with a docking score of &#x02212;9.6&#x02009;Kcal/mol and MM-GBSA dG binding energy &#x02212;66.6&#x02009;Kcal/mol. Similar to Delphinidin 3,5-diglucoside and scutellarein 7-glucoside, the alpha-L-arabinofuranosy moiety of avicularin is majorly involved in interaction with the main residues (CYS<sup>145</sup> and GLU<sup>166</sup>) of the catalytic site via hydrogen bonding. To further increase the binding affinity, the benzene ring forms &#x003c0;-&#x003c0; stacking with the HIE<sup>41</sup> of the hydrophobic subsite. Also the hydroxyl group of chromone nucleus and benzene ring were found to interact with the THR<sup>190</sup> and HIS<sup>164</sup>, CYS<sup>145</sup>, respectively through hydrogen bonding, enhancing the fit into the active site (<xref ref-type="fig" rid="F0003">Figure 3(iii)</xref>). On the other hand avicularin has highest MM-GBSA dG binding energy of &#x02212;44.50&#x02009;Kcal/mol among all top leads for ACE2 enzyme. The hydroxyls of the alpha-L-arabinofuranosy moiety and phenyl ring shows binding interaction with residues GLU<sup>406</sup>, THR<sup>445</sup>, ASP<sup>367</sup> and ASH<sup>368</sup> of domain I. Docking poses also reveals the presence of multiple &#x003c0;-cation interaction between chromone nucleus and ARG<sup>273</sup>. The carbonyl group of main nucleus was found to be bonded with ARG<sup>518</sup> through hydrogen bonding (<xref ref-type="fig" rid="F0004">Figure 4(iii)</xref>).</p><p>Out of top 4 screened leads 3,5-Di-O-galloylshikimic acid have the highest MM-GBSA dG binding energy of &#x02212;35.09&#x02009;Kcal/mol with docking score of &#x02212;10.3&#x02009;kcal/mol for M<sup>pro</sup>. It is also the only lead among top four that lacks a sugar moiety. To fit inside the M<sup>pro</sup> cavity, the hydroxyl groups of benzoyl moiety are involved in H-bonding with the S4 subsite residues (THR<sup>190</sup>), and S1 subsite residues (HIS<sup>163</sup>, ASN<sup>142</sup>). The hydroxyl group and the oxygen atoms of both the benzoyl groups are found to interact with the LEU<sup>167</sup>, GLY<sup>143</sup> and GLU<sup>166</sup> (<xref ref-type="fig" rid="F0003">Figure 3(iv)</xref>).</p><p>However for ACE2, 3,5-Di-O-galloylshikimic acid has the 3<sup>rd</sup> lowest MM-GBSA dG binding energy of &#x02212;51.7&#x02009;Kcal/mol with docking score of &#x02212;11.16&#x02009;kcal/mol. From the docked poses inside ACE2 catalytic site, it can be concluded that oxygen of the carboxylate was found to interact with HIE<sup>505</sup> and HIE<sup>345</sup> through hydrogen bonding and with ARG<sup>273</sup> through non-covalent ionic interaction (salt bridge). The hydroxyls of the benzoyl moiety were displaying hydrogen bonding interaction with the TYR<sup>127</sup> and GLU<sup>406</sup>. HIE<sup>345</sup> of the side chain was involved in the &#x003c0;-&#x003c0; stacking interaction with one of the benzoyl ring (<xref ref-type="fig" rid="F0004">Figure 4(iv)</xref>). The docking score of all the screened natural secondary metabolites is shown in <xref ref-type="fig" rid="F0005">Figure 5</xref>.</p><fig id="F0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Docking scores of screened natural ligands. Parentheses contain (Source of the natural product [reference]).</p></caption><graphic content-type="color" xlink:href="TBSD_A_1794970_F0005_C"/></fig><p>To be eligible for clinical evaluation, pharmacokinetic profile of a drug plays pivotal role. Based on the results of ADME calculations all the investigated leads have low bioavailability score. The bioavailability score (ABS) depends on passing or violating Lipinski&#x02019;s rule of five. At biological pH, a compound is expected to have &#x0003e;10% bioavailability (F) in rat only if it pass Lipinski&#x02019;s rule of five with ABS 0.55 (i.e. 55% chances of <italic>F</italic>&#x02009;&#x0003e;&#x02009;10% in rat). However if it fails, ABS is only 0.17 i.e. 17% chance for a molecule to have bioavailability &#x0003e;10% in rat (Martin, <xref rid="CIT0027" ref-type="bibr">2005</xref>). With ABS-0.17, delphinidin 3,5-diglucoside (an anthocyanin), the bioavailability through gastro intestinal tract (GIT) is reported to be very low. A study reported by McGhie and Walton (<xref rid="CIT0029" ref-type="bibr">2007</xref>) concluded that in animals and humans low anthocyanins levels are absorbed in the circulation and excreted in urine, but high levels are found in the gastrointestinal (GI) tract. Another investigation by Paul et&#x000a0;al. (<xref rid="CIT0035" ref-type="bibr">2018</xref>) suggests that anthocyanins in the form of crude extract have less bioavailability as compared to encapsulated spray dried formulations. Like delphinidin 3,5-diglucoside the next two leads (Scutellarein 7-glucoside, Avicularin) which are glycosidic flavonoids also have less bioavailability with acceptable water solubility limit. Glycosidic flavonoids show less permeability through GIT (Arts et&#x000a0;al., <xref rid="CIT0002" ref-type="bibr">2004</xref>). Hollman et&#x000a0;al. reported that only aglycone part of flavonoids pass through the intestinal membrane and glycone moiety mostly gets digested in the GIT with time to reach peak concentrations (T<sub>max</sub>) between &#x0003c;0.5 and 9&#x02009;h (Walle, <xref rid="CIT0044" ref-type="bibr">2004</xref>). The 3,5-Di-O-galloylshikimic acid (gallotanin with quinic acid core) estimated log S value suggest that it has acceptable water solubility due to presence of polar functional groups, yet its bioavailability score is only 0.11.</p><p>Both from docking and ADME analysis, it is clear that the sugar moieties and other polar groups are both responsible for the high binding affinity to M<sup>pro</sup>/ACE2 and low oral bioavailability. Among other natural compounds reported to bind with M<sup>pro</sup> and ACE2, Epigallocatechin gallate (EGCG) (Khaerunnisa et&#x000a0;al., <xref rid="CIT0022" ref-type="bibr">2020</xref>; Lalit &#x00026; Vyomesh, <xref rid="CIT0023" ref-type="bibr">2020</xref>; Mittal et&#x000a0;al., <xref rid="CIT0032" ref-type="bibr">2020</xref>) and Theaflavin-3,3-digallate (Manish, <xref rid="CIT0026" ref-type="bibr">2020</xref>) also showed very good binding to M<sup>pro</sup> and ACE2, but has poor oral bioavailability (ABS-0.17) (<xref ref-type="fig" rid="F0006">Figure 6</xref>). Specifically, EGCG has been reported to be broken down in large intestine by the colonic microflora. The fraction of EGCG that is absorbed might undergo rapid methylation catalyzed by liver cytosolic catechol-<italic>O</italic>-methyltransferase which decreases its hydrophilicity (Mereles &#x00026; Hunstein, <xref rid="CIT0030" ref-type="bibr">2011</xref>), the key feature found responsible for M<sup>pro</sup> inhibition. Thus a majority of the natural molecules with therapeutic potential against SARS-CoVs require an effective way to get delivered to lung in their native form to bypass degradation and metabolism associated with oral route.</p><fig id="F0006" orientation="portrait" position="float"><label>Figure 6.</label><caption><p>ADME properties of screened natural ligands. ABS = 0.11<sup>#</sup> or 0.17* or 0.55**.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1794970_F0006_C"/></fig></sec><sec sec-type="conclusions" id="S0004" disp-level="1"><title>Conclusion</title><p>Traditional medicines in different countries have history of successfully treating several epidemics and endemics. With advanced drug discovery tools in place, it is feasible to screen active ingredients of these natural concoctions for potential antiviral application. We attempted to explore this approach by screening selected natural secondary metabolites for their dual binding potential to (1) viral main protease M<sup>pro</sup> that has a conserved catalytic cleavage site responsible for post-translational processing of polyproteins required for viral replication in all SARS corona viruses and (2) ACE2 the principle receptor responsible for entry of the viral particles into the host cells. The top four leads Delphinidin 3,5-diglucoside, Scutellarein 7-glucoside, Avicularin and 3,5-Di-O-galloylshikimic acid showed encouraging binding affinity with MM-GBSA energies up to &#x02212;74.0&#x02009;Kcal/mol and &#x02212;79.5&#x02009;Kcal/mol to M<sup>pro</sup> and ACE2, respectively. However, their theoretical bioavailability score (ABS) of 0.11 or 0.17 makes them ineffective via oral route. Potential natural leads such as Delphinidin 3, 5-diglucoside, an anthocyanin responsible for the red pigmentation of pomegranate juice, are ingested orally. Nonetheless, their viral inhibitory potential is greatly limited by low oral bioavailability. To overcome this bottleneck, these molecules can be either engineered to withstand GIT degradation and first pass metabolism or can be encapsulated in nano/microparticles towards their site specific pulmonary delivery.</p></sec></body><back><ack><title>Acknowledgements</title><p>PS is thankful for JRF fellowship received under DBT funded project under Nanobiotechnology scheme (BT/PR21972/NNT/28/1280/2017). AS acknowledge the Government of India for funding under DST-SERB core research grant scheme (EMR/2016/003851). The authors sincerely acknowledge the support received from NIPER, S.A.S Nagar in performing molecular docking studies. AS thank Dr.Victor Arokia Doss (Associate Professor, Dept of Biochemistry) and Late. Dr.N.Abitha Devi (Ex-HoD, Dept of Biochemistry), PSG College of Arts and Science for mentorship and support.</p></ack><sec id="S0005" disp-level="1" sec-type="COI-statement"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the authors.</p></sec><ref-list><title>References</title><ref id="CIT0001"><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Farag, A., Wang, P., Ahmed, M., and Sadek, H. (2020). Identification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning (Version 2).</collab></person-group>
<pub-id pub-id-type="doi">10.26434/CHEMRXIV.12049647.V1</pub-id>.</mixed-citation></ref><ref id="CIT0002"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arts</surname><given-names>I. C. W.</given-names></name>, <name name-style="western"><surname>Sesink</surname><given-names>A. L. A.</given-names></name>, <name name-style="western"><surname>Faassen-Peters</surname><given-names>M.</given-names></name>, &#x00026; <name name-style="western"><surname>Hollman</surname><given-names>P. C. H.</given-names></name></person-group> (<year>2004</year>). <article-title>The type of sugar moiety is a major determinant of the small intestinal uptake and subsequent biliary excretion of dietary quercetin glycosides</article-title>. <source><italic toggle="yes">The British Journal of Nutrition</italic></source>, (<issue>6</issue>), <fpage>841</fpage>&#x02013;<lpage>847</lpage>. <pub-id pub-id-type="doi">10.1079/BJN20041123</pub-id></mixed-citation></ref><ref id="CIT0004"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name>, &#x00026; <name name-style="western"><surname>Lai</surname><given-names>L.</given-names></name></person-group> (<year>2007</year>). <article-title>Computation of octanol-water partition coefficients by guiding an additive model with knowledge</article-title>. <source><italic toggle="yes">Journal of Chemical Information and Modeling</italic></source>, (<issue>6</issue>), <fpage>2140</fpage>&#x02013;<lpage>2148</lpage>. <pub-id pub-id-type="doi">10.1021/ci700257y</pub-id><pub-id pub-id-type="pmid">17985865</pub-id></mixed-citation></ref><ref id="CIT0005"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coleman</surname><given-names>C. M.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y. V.</given-names></name>, <name name-style="western"><surname>Mu</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>J. K.</given-names></name>, <name name-style="western"><surname>Massare</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Flyer</surname><given-names>D. C.</given-names></name>, <name name-style="western"><surname>Glenn</surname><given-names>G. M.</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>G. E.</given-names></name>, &#x00026; <name name-style="western"><surname>Frieman</surname><given-names>M. B.</given-names></name></person-group> (<year>2014</year>). <article-title>Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice</article-title>. <source><italic toggle="yes">Vaccine</italic></source>, (<issue>26</issue>), <fpage>3169</fpage>&#x02013;<lpage>3174</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.04.016</pub-id><pub-id pub-id-type="pmid">24736006</pub-id></mixed-citation></ref><ref id="CIT0006"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daina</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Michielin</surname><given-names>O.</given-names></name>, &#x00026; <name name-style="western"><surname>Zoete</surname><given-names>V.</given-names></name></person-group> (<year>2017</year>). <article-title>SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</article-title>. <source><italic toggle="yes">Scientific Reports</italic></source>, , <fpage>42717</fpage>&#x02013;<lpage>42713</lpage>. <pub-id pub-id-type="doi">10.1038/srep42717</pub-id><pub-id pub-id-type="pmid">28256516</pub-id></mixed-citation></ref><ref id="CIT0007"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Sarmah</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Lyndem</surname><given-names>S.</given-names></name>, &#x00026; <name name-style="western"><surname>Roy</surname><given-names>A. S.</given-names></name></person-group> (<year>2020</year>). <article-title>An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study</article-title>. &#x0201d; <italic>Journal of Biomolecular Structure and Dynamics</italic>, May, 1&#x02013;11. <pub-id pub-id-type="doi">10.1080/07391102.2020.1763201</pub-id>.</mixed-citation></ref><ref id="CIT0008"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delaney</surname><given-names>J. S.</given-names></name></person-group> (<year>2004</year>). <article-title>ESOL: Estimating aqueous solubility directly from molecular structure</article-title>. <source><italic toggle="yes">Journal of Chemical Information and Computer Sciences</italic></source>, (<issue>3</issue>), <fpage>1000</fpage>&#x02013;<lpage>1005</lpage>. <pub-id pub-id-type="doi">10.1021/ci034243x</pub-id><pub-id pub-id-type="pmid">15154768</pub-id></mixed-citation></ref><ref id="CIT0010"><mixed-citation publication-type="web"><person-group person-group-type="author"><collab>Emam, A. M., R. Elias, A. M. Moussa, R. Faure, L. Debrauwer, and G. Balansard. (1998). Two Flavonoid Triglycosides from Buddleja Madagascariensis.</collab></person-group>
<italic>Phytochemistry, 48</italic>(4), 739&#x02013;42. <pub-id pub-id-type="doi">10.1016/S0031-9422(97)01043-1</pub-id>.</mixed-citation></ref><ref id="CIT0011"><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>FDA</collab></person-group> (<year>2020</year>). <article-title>Hydroxychloroquine fact sheet for health care providers</article-title>, <fpage>1</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="CIT0012"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filipiak</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Hidalgo</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Silvan</surname><given-names>J. M.</given-names></name>, <name name-style="western"><surname>Fabre</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Carbajo</surname><given-names>R. J.</given-names></name>, <name name-style="western"><surname>Pineda-Lucena</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Ramos</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>De Pascual-Teresa</surname><given-names>B.</given-names></name>, &#x00026; <name name-style="western"><surname>De Pascual-Teresa</surname><given-names>S.</given-names></name></person-group> (<year>2014</year>). <article-title>Dietary gallic acid and anthocyanin cytotoxicity on human fibrosarcoma HT1080 cells. A study on the mode of action</article-title>. <source><italic toggle="yes">Food &#x00026; Function</italic></source>, (<issue>2</issue>), <fpage>381</fpage>&#x02013;<lpage>389</lpage>. <pub-id pub-id-type="doi">10.1039/c3fo60465a</pub-id><pub-id pub-id-type="pmid">24413695</pub-id></mixed-citation></ref><ref id="CIT0013"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friesner</surname><given-names>R. A.</given-names></name>, <name name-style="western"><surname>Banks</surname><given-names>J. L.</given-names></name>, <name name-style="western"><surname>Murphy</surname><given-names>R. B.</given-names></name>, <name name-style="western"><surname>Halgren</surname><given-names>T. A.</given-names></name>, <name name-style="western"><surname>Klicic</surname><given-names>J. J.</given-names></name>, <name name-style="western"><surname>Mainz</surname><given-names>D. T.</given-names></name>, <name name-style="western"><surname>Repasky</surname><given-names>M. P.</given-names></name>, <name name-style="western"><surname>Knoll</surname><given-names>E. H.</given-names></name>, <name name-style="western"><surname>Shelley</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Perry</surname><given-names>J. K.</given-names></name>, <name name-style="western"><surname>Shaw</surname><given-names>D. E.</given-names></name>, <name name-style="western"><surname>Francis</surname><given-names>P.</given-names></name>, &#x00026; <name name-style="western"><surname>Shenkin</surname><given-names>P. S.</given-names></name></person-group> (<year>2004</year>). <article-title>Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy</article-title>. <source><italic toggle="yes">Journal of Medicinal Chemistry</italic></source>, (<issue>7</issue>), <fpage>1739</fpage>&#x02013;<lpage>1749</lpage>. <pub-id pub-id-type="doi">10.1021/jm0306430</pub-id><pub-id pub-id-type="pmid">15027865</pub-id></mixed-citation></ref><ref id="CIT0014"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujimori</surname><given-names>K.</given-names></name>, &#x00026; <name name-style="western"><surname>Shibano</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Avicularin, a plant flavonoid, suppresses lipid accumulation through repression of C/EBP&#x003b1;-activated GLUT4-mediated glucose uptake in 3T3-L1 cells</article-title>. <source><italic toggle="yes">Journal of Agricultural and Food Chemistry</italic></source>, (<issue>21</issue>), <fpage>5139</fpage>&#x02013;<lpage>5147</lpage>. <pub-id pub-id-type="doi">10.1021/jf401154c</pub-id><pub-id pub-id-type="pmid">23647459</pub-id></mixed-citation></ref><ref id="CIT0015"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukunaga</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Nishiya</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Kajikawa</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Takeya</surname><given-names>K.</given-names></name>, &#x00026; <name name-style="western"><surname>Itokawa</surname><given-names>H.</given-names></name></person-group> (<year>1989</year>). <article-title>Studies on the constituents of Japanese mistletoes from different host trees, and their antimicrobial and hypotensive properties</article-title>. <source><italic toggle="yes">Chemical &#x00026; Pharmaceutical Bulletin</italic></source>, (<issue>6</issue>), <fpage>1543</fpage>&#x02013;<lpage>1546</lpage>. <pub-id pub-id-type="doi">10.1248/cpb.37.1543</pub-id><pub-id pub-id-type="pmid">2776238</pub-id></mixed-citation></ref><ref id="CIT0016"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gautret</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Lagier</surname><given-names>J.-C.</given-names></name>, <name name-style="western"><surname>Parola</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Hoang</surname><given-names>V. T.</given-names></name>, <name name-style="western"><surname>Meddeb</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Mailhe</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Doudier</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Courjon</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Giordanengo</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Vieira</surname><given-names>V. E.</given-names></name>, <name name-style="western"><surname>Dupont</surname><given-names>H. T.</given-names></name>, <name name-style="western"><surname>Honor&#x000e9;</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Colson</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Chabri&#x000e8;re</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>La Scola</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Rolain</surname><given-names>J.-M.</given-names></name>, <name name-style="western"><surname>Brouqui</surname><given-names>P.</given-names></name>, &#x00026; <name name-style="western"><surname>Raoult</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial</article-title>. <source><italic toggle="yes">International Journal of Antimicrobial Agents</italic></source>,<fpage>&#x000a0;105949</fpage>
<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105949</pub-id></mixed-citation></ref><ref id="CIT0017"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guimar&#x000e3;es</surname><given-names>C. R. W.</given-names></name>, &#x00026; <name name-style="western"><surname>Cardozo</surname><given-names>M.</given-names></name></person-group> (<year>2008</year>). <article-title>MM-GB/SA rescoring of docking poses in structure-based lead optimization</article-title>. <source><italic toggle="yes">Journal of Chemical Information and Modeling</italic></source>, (<issue>5</issue>), <fpage>958</fpage>&#x02013;<lpage>970</lpage>. <pub-id pub-id-type="doi">10.1021/ci800004w</pub-id><pub-id pub-id-type="pmid">18422307</pub-id></mixed-citation></ref><ref id="CIT0018"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>X. F.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>J. P.</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>S. Q.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name>, &#x00026; <name name-style="western"><surname>De Sun</surname><given-names>W.</given-names></name></person-group> (<year>2018</year>). <article-title>Avicularin reversed multidrug-resistance in human gastric cancer through enhancing Bax and BOK expressions</article-title>. <source><italic toggle="yes">Biomedicine &#x00026; Pharmacotherapy&#x02009;=&#x02009;Biomedecine &#x00026; Pharmacotherapie</italic></source>, , <fpage>67</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2018.03.110</pub-id></mixed-citation></ref><ref id="CIT0019"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Ai</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>He</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Ding</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Lv</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Hassan</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name>, &#x00026; <name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name></person-group> (<year>2018</year>). <article-title>Genomic characterization and infectivity of a novel SARS-like coronavirus in Chinese bats</article-title>. <source><italic toggle="yes">Emerging Microbes &#x00026; Infections</italic></source>, (<issue>1</issue>), <fpage>1</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1038/s41426-018-0155-5</pub-id><pub-id pub-id-type="pmid">29323102</pub-id></mixed-citation></ref><ref id="CIT0020"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Islam</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Parves</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Paul</surname><given-names>A. S.</given-names></name>, <name name-style="western"><surname>Uddin</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Rahman</surname><given-names>M. S.</given-names></name>, <name name-style="western"><surname>Mamun</surname><given-names>A. A.</given-names></name>, <name name-style="western"><surname>Hossain</surname><given-names>M. N.</given-names></name>, <name name-style="western"><surname>Ali</surname><given-names>M. A.</given-names></name>, &#x00026; <name name-style="western"><surname>Halim</surname><given-names>M. A.</given-names></name></person-group> (<year>2020</year>). <article-title>A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure &#x00026; Dynamics</italic></source>, <fpage>1</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1761883</pub-id>.</mixed-citation></ref><ref id="CIT0021"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Peng</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Duan</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>You</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>, &#x02026; <name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name></person-group> (<year>2020</year>). <article-title>Structure of Mpro from COVID-19 virus and discovery of its inhibitors</article-title>. <source><italic toggle="yes">Nature</italic></source>, (<issue>7811</issue>), <fpage>289</fpage>&#x02013;<lpage>293</lpage>. . <pub-id pub-id-type="doi">10.1038/s41586-020-2223-y</pub-id><pub-id pub-id-type="pmid">32272481</pub-id></mixed-citation></ref><ref id="CIT0022"><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Khaerunnisa</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Kurniawan</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Awaluddin</surname><given-names>R.</given-names></name>, &#x00026; <name name-style="western"><surname>Suhartati</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Potential inhibitor of COVID-19 main protease (M pro) from several medicinal plant compounds by molecular docking study</article-title>. Preprints, <fpage>1</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.20944/preprints202003.0226.v1</pub-id>.</mixed-citation></ref><ref id="CIT0023"><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Lalit</surname><given-names>S.</given-names></name>, &#x00026; <name name-style="western"><surname>Vyomesh</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). Comparative docking analysis of rational drugs against COVID-19 main protease. ChemRxiv. <pub-id pub-id-type="doi">10.26434/chemrxiv.12136002.v1</pub-id>.</mixed-citation></ref><ref id="CIT0024"><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Liang</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name>, &#x00026; <name name-style="western"><surname>Lai</surname><given-names>L.</given-names></name></person-group> (<year>2020</year>). <italic>Scutellaria baicalensis</italic> extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in&#x000a0;vitro. BioRxiv, 2020.04.10.035824. <pub-id pub-id-type="doi">10.1101/2020.04.10.035824</pub-id>.</mixed-citation></ref><ref id="CIT0025"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Niu</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Bi</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Zhan</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name>, &#x02026; <name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name></person-group> (<year>2020</year>). <article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding</article-title>. <source><italic toggle="yes">The Lancet</italic></source>, (<issue>10224</issue>), <fpage>565</fpage>&#x02013;<lpage>574</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30251-8</pub-id></mixed-citation></ref><ref id="CIT0026"><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Manish</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). Studies on computational molecular interaction between SARS-CoV-2 main protease and natural products. ChemRxiv, Preprint. <pub-id pub-id-type="doi">10.26434/chemrxiv.12024789.v1</pub-id>.</mixed-citation></ref><ref id="CIT0027"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>Y. C.</given-names></name></person-group> (<year>2005</year>). <article-title>A bioavailability score</article-title>. <source><italic toggle="yes">Journal of Medicinal Chemistry</italic></source>, (<issue>9</issue>), <fpage>3164</fpage>&#x02013;<lpage>3170</lpage>. <pub-id pub-id-type="doi">10.1021/jm0492002</pub-id><pub-id pub-id-type="pmid">15857122</pub-id></mixed-citation></ref><ref id="CIT0028"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazewski</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>M. S.</given-names></name>, &#x00026; <name name-style="western"><surname>Gonzalez de Mejia</surname><given-names>E.</given-names></name></person-group> (<year>2019</year>). <article-title>Anthocyanins, delphinidin-3-O-glucoside and cyanidin-3-O-glucoside, inhibit immune checkpoints in human colorectal cancer cells in&#x000a0;vitro and in silico</article-title>. <source><italic toggle="yes">Scientific Reports</italic></source>, (<issue>1</issue>), <fpage>1</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1038/s41598-019-47903-0</pub-id><pub-id pub-id-type="pmid">30626917</pub-id></mixed-citation></ref><ref id="CIT0029"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGhie</surname><given-names>T. K.</given-names></name>, &#x00026; <name name-style="western"><surname>Walton</surname><given-names>M. C.</given-names></name></person-group> (<year>2007</year>). <article-title>The bioavailability and absorption of anthocyanins: Towards a better understanding</article-title>. <source><italic toggle="yes">Molecular Nutrition &#x00026; Food Research</italic></source>, (<issue>6</issue>), <fpage>702</fpage>&#x02013;<lpage>713</lpage>. <pub-id pub-id-type="doi">10.1002/mnfr.200700092</pub-id><pub-id pub-id-type="pmid">17533653</pub-id></mixed-citation></ref><ref id="CIT0030"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mereles</surname><given-names>D.</given-names></name>, &#x00026; <name name-style="western"><surname>Hunstein</surname><given-names>W.</given-names></name></person-group> (<year>2011</year>). <article-title>Epigallocatechin-3-Gallate (EGCG) for clinical trials: More pitfalls than promises?</article-title>
<source><italic toggle="yes">International Journal of Molecular Sciences</italic></source>, (<issue>9</issue>), <fpage>5592</fpage>&#x02013;<lpage>5603</lpage>. <pub-id pub-id-type="doi">10.3390/ijms12095592</pub-id><pub-id pub-id-type="pmid">22016611</pub-id></mixed-citation></ref><ref id="CIT0031"><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Micael</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>de Oliveira</surname><given-names>L.</given-names></name>, &#x00026; <name name-style="western"><surname>de Oliveira Kelson Mota</surname><given-names>T.</given-names></name></person-group> (<year>2020</year>). Comparative computational study of SARS-CoV-2 receptors antagonists from already approved drugs. ChemRxiv. <pub-id pub-id-type="doi">10.26434/chemrxiv.12044538.v2</pub-id>.</mixed-citation></ref><ref id="CIT0032"><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Mittal</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Kumari</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Srivastava</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name>, &#x00026; <name name-style="western"><surname>Asthana</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach. ChemRxiv, (1). Preprint. <pub-id pub-id-type="doi">10.26434/CHEMRXIV.12086565.V2</pub-id>.</mixed-citation></ref><ref id="CIT0033"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okonogi</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Kheawfu</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Holzer</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Unger</surname><given-names>F. M.</given-names></name>, <name name-style="western"><surname>Viernstein</surname><given-names>H.</given-names></name>, &#x00026; <name name-style="western"><surname>Mueller</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Anti-inflammatory effects of compounds from Polygonum odoratum</article-title>. <source><italic toggle="yes">Natural Product Communications</italic></source>, (<issue>11</issue>), <fpage>1651</fpage>&#x02013;<lpage>1654</lpage>. <pub-id pub-id-type="doi">10.1177/1934578X1601101107</pub-id><pub-id pub-id-type="pmid">30475499</pub-id></mixed-citation></ref><ref id="CIT0034"><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Pandit</surname><given-names>M.</given-names></name></person-group> n.d. <article-title>In silico studies reveal potential antiviral activity of phytochemicals from medicinal plants for the treatment of COVID-19 infection</article-title>. <fpage>1</fpage>&#x02013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.21203/rs.3.rs-22687/v1</pub-id>.</mixed-citation></ref><ref id="CIT0035"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paul</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Banerjee</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Goon</surname><given-names>A.</given-names></name>, &#x00026; <name name-style="western"><surname>Saha</surname><given-names>S.</given-names></name></person-group> (<year>2018</year>). <article-title>Chemo-profiling of anthocyanins and fatty acids present in pomegranate aril and seed grown in Indian condition and its bioaccessibility study</article-title>. <source><italic toggle="yes">Journal of Food Science and Technology</italic></source>, (<issue>7</issue>), <fpage>2488</fpage>&#x02013;<lpage>2496</lpage>. <pub-id pub-id-type="doi">10.1007/s13197-018-3166-2</pub-id><pub-id pub-id-type="pmid">30042564</pub-id></mixed-citation></ref><ref id="CIT0036"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rehecho</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Hidalgo</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Garc&#x000ed;a-I&#x000f1;iguez de Cirano</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Navarro</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Astiasar&#x000e1;n</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Ansorena</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Cavero</surname><given-names>R. Y.</given-names></name>, &#x00026; <name name-style="western"><surname>Calvo</surname><given-names>M. I.</given-names></name></person-group> (<year>2011</year>). <article-title>Chemical composition, mineral content and antioxidant activity of Verbena officinalis L</article-title>. <source><italic toggle="yes">LWT - Food Science and Technology</italic></source>, (<issue>4</issue>), <fpage>875</fpage>&#x02013;<lpage>882</lpage>. <pub-id pub-id-type="doi">10.1016/j.lwt.2010.11.035</pub-id></mixed-citation></ref><ref id="CIT0037"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rhoades</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Remdesivir EUA letter of authorization</article-title>. , <fpage>1</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="CIT0038"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roh</surname><given-names>C.</given-names></name></person-group> (<year>2012</year>). <article-title>A facile inhibitor screening of SARS coronavirus N protein using nanoparticle-based RNA oligonucleotide</article-title>. <source><italic toggle="yes">International Journal of Nanomedicine</italic></source>, , <fpage>2173</fpage>&#x02013;<lpage>2179</lpage>. <pub-id pub-id-type="doi">10.2147/IJN.S31379</pub-id><pub-id pub-id-type="pmid">22619553</pub-id></mixed-citation></ref><ref id="CIT0039"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rota</surname><given-names>P. A.</given-names></name>, <name name-style="western"><surname>Oberste</surname><given-names>M. S.</given-names></name>, <name name-style="western"><surname>Monroe</surname><given-names>S. S.</given-names></name>, <name name-style="western"><surname>Nix</surname><given-names>W. A.</given-names></name>, <name name-style="western"><surname>Campagnoli</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Icenogle</surname><given-names>J. P.</given-names></name>, <name name-style="western"><surname>Pe&#x000f1;aranda</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Bankamp</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Maher</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>M.-H.</given-names></name>, <name name-style="western"><surname>Tong</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Tamin</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Lowe</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Frace</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>DeRisi</surname><given-names>J. L.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Erdman</surname><given-names>D. D.</given-names></name>, <name name-style="western"><surname>Peret</surname><given-names>T. C. T.</given-names></name>, &#x02026; <name name-style="western"><surname>Bellini</surname><given-names>W. J.</given-names></name></person-group> (<year>2003</year>). <article-title>Characterization of a novel coronavirus associated with severe acute respiratory syndrome</article-title>. <source><italic toggle="yes">Science</italic></source>, (<issue>5624</issue>), <fpage>1394</fpage>&#x02013;<lpage>1399</lpage>. <pub-id pub-id-type="doi">10.1126/science.1085952</pub-id></mixed-citation></ref><ref id="CIT0040"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stenlid</surname><given-names>G.</given-names></name></person-group> (<year>1976</year>). <article-title>Effects of substituents in the A-ring on the physiological activity of flavones</article-title>. <source><italic toggle="yes">Phytochemistry</italic></source>, (<issue>6</issue>), <fpage>911</fpage>&#x02013;<lpage>912</lpage>. <pub-id pub-id-type="doi">10.1016/S0031-9422(00)84368-X</pub-id></mixed-citation></ref><ref id="CIT0041"><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Tallei</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Tumilaar</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Niode</surname><given-names>N.</given-names></name>, Fatimawali, <name name-style="western"><surname>Kepel</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Idroes</surname><given-names>R.</given-names></name> &#x00026; <name name-style="western"><surname>Effendi</surname><given-names>Y.</given-names></name></person-group> (<year>2020</year>). <article-title>Potential of plant bioactive compounds as SARS-CoV-2 main protease (Mpro) and spike (S) glycoprotein inhibitors: A molecular docking study</article-title>. Preprints, no. 1&#x02013;18. <pub-id pub-id-type="doi">10.20944/preprints202004.0102.v1</pub-id>.</mixed-citation></ref><ref id="CIT0042"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Towler</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Staker</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Prasad</surname><given-names>S. G.</given-names></name>, <name name-style="western"><surname>Menon</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Parsons</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Ryan</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Fisher</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Dales</surname><given-names>N. A.</given-names></name>, <name name-style="western"><surname>Patane</surname><given-names>M. A.</given-names></name>, &#x00026; <name name-style="western"><surname>Pantoliano</surname><given-names>M. W.</given-names></name></person-group> (<year>2004</year>). <article-title>ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis</article-title>. <source><italic toggle="yes">The Journal of Biological Chemistry</italic></source>, (<issue>17</issue>), <fpage>17996</fpage>&#x02013;<lpage>17997</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M311191200</pub-id><pub-id pub-id-type="pmid">14754895</pub-id></mixed-citation></ref><ref id="CIT0043"><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Ubani</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Agwom</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Shehu</surname><given-names>N. Y.</given-names></name>, <name name-style="western"><surname>Luka</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Umera</surname><given-names>E. A.</given-names></name>, <name name-style="western"><surname>Umar</surname><given-names>U.</given-names></name>, <name name-style="western"><surname>Omale</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Nnadi</surname><given-names>E.</given-names></name>, &#x00026; <name name-style="western"><surname>Aguiyi</surname><given-names>J. C.</given-names></name></person-group> (<year>2020</year>). <article-title>Molecular docking analysis of some phytochemicals on two SARS-CoV-2 targets</article-title>. BioRxiv, 2020.03.31.017657. <pub-id pub-id-type="doi">10.1101/2020.03.31.017657</pub-id>.</mixed-citation></ref><ref id="CIT0044"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walle</surname><given-names>T.</given-names></name></person-group> (<year>2004</year>). <article-title>Absorption and metabolism of flavonoids</article-title>. <source><italic toggle="yes">Free Radical Biology &#x00026; Medicine</italic></source>, (<issue>7</issue>), <fpage>829</fpage>&#x02013;<lpage>837</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2004.01.002</pub-id><pub-id pub-id-type="pmid">15019968</pub-id></mixed-citation></ref><ref id="CIT0045"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>W.</given-names></name>, &#x00026; <name name-style="western"><surname>Xiao</surname><given-names>G.</given-names></name></person-group> (<year>2020</year>). <article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-NCoV) in&#x000a0;vitro</article-title>. <source><italic toggle="yes">Cell Research</italic></source>, (<issue>3</issue>), <fpage>269</fpage>&#x02013;<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id><pub-id pub-id-type="pmid">32020029</pub-id></mixed-citation></ref><ref id="CIT0046"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Niu</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Qiao</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Yuen</surname><given-names>K.-Y.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name>, &#x00026; <name name-style="western"><surname>Qi</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Structural and functional basis of SARS-CoV-2 entry by using human ACE2</article-title>. <source><italic toggle="yes">Cell</italic></source>, (<issue>4</issue>), <fpage>894</fpage>&#x02013;<lpage>904.e9</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.03.045</pub-id><pub-id pub-id-type="pmid">32275855</pub-id></mixed-citation></ref><ref id="CIT0047"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y.-M.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>Z.-G.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Tao</surname><given-names>Z.-W.</given-names></name>, <name name-style="western"><surname>Tian</surname><given-names>J.-H.</given-names></name>, <name name-style="western"><surname>Pei</surname><given-names>Y.-Y.</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>M.-L.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y.-L.</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>F.-H.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Q.-M.</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>J.-J.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Holmes</surname><given-names>E. C.</given-names></name>, &#x00026; <name name-style="western"><surname>Zhang</surname><given-names>Y.-Z.</given-names></name></person-group> (<year>2020</year>). <article-title>A new coronavirus associated with human respiratory disease in China</article-title>. <source><italic toggle="yes">Nature</italic></source>, (<issue>7798</issue>), <fpage>265</fpage>&#x02013;<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2008-3</pub-id></mixed-citation></ref><ref id="CIT0048"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Cui</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Niu</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Zhan</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name>, &#x00026; <name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 1&#x02013;8</article-title>. <source><italic toggle="yes">Clinical Infectious Diseases</italic></source>. . <pub-id pub-id-type="doi">10.1093/cid/ciaa237</pub-id></mixed-citation></ref><ref id="CIT0049"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Qi</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name>, &#x00026; <name name-style="western"><surname>Gao</surname><given-names>G. F.</given-names></name></person-group> (<year>2017</year>). <article-title>Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains</article-title>. <source><italic toggle="yes">Nature Communications</italic></source>, , <fpage>15092</fpage>&#x02013;<lpage>15099</lpage>. <pub-id pub-id-type="doi">10.1038/ncomms15092</pub-id></mixed-citation></ref><ref id="CIT0050"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuldashev</surname><given-names>M. P.</given-names></name></person-group> (<year>2002</year>). <article-title>Flavonoids of the aerial part of Trigonella grandiflora</article-title>. <source><italic toggle="yes">Chemistry of Natural Compounds</italic></source>, (<issue>3</issue>), <fpage>291</fpage>&#x02013;<lpage>292</lpage>. <pub-id pub-id-type="doi">10.1023/A:1020448531522</pub-id></mixed-citation></ref><ref id="CIT0100"><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>Zhang, X. Q., and Xu, L. S. (1989). Determination of avicularin in Polygonum aviculare L. by square wave polarography.&#x000a0;</collab></person-group><italic>Proc Chin Acad Med Sci Peking Union Med Coll,</italic>
<italic>4</italic>(4),193&#x02013;195.</mixed-citation></ref><ref id="CIT0051"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Penninger</surname><given-names>J. M.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>N.</given-names></name>, &#x00026; <name name-style="western"><surname>Slutsky</surname><given-names>A. S.</given-names></name></person-group> (<year>2020</year>). <article-title>Angiotensin-Converting Enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target</article-title>. <source><italic toggle="yes">Intensive Care Medicine</italic></source>, (<issue>4</issue>), <fpage>586</fpage>&#x02013;<lpage>590</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-020-05985-9</pub-id><pub-id pub-id-type="pmid">32125455</pub-id></mixed-citation></ref><ref id="CIT0052"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>X.-L.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X.-G.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Si</surname><given-names>H.-R.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>C.-L.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>H.-D.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>R.-D.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>M.-Q.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>X.-R.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name>, &#x02026; <name name-style="western"><surname>Shi</surname><given-names>Z.-L.</given-names></name></person-group> (<year>2020</year>). <article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>. <source><italic toggle="yes">Nature</italic></source>, (<issue>7798</issue>), <fpage>270</fpage>&#x02013;<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id><pub-id pub-id-type="pmid">32015507</pub-id></mixed-citation></ref><ref id="CIT0053"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>W.</given-names></name>, &#x00026; <name name-style="western"><surname>Cheng</surname><given-names>F.</given-names></name></person-group> (<year>2020</year>). <article-title>Network-based drug repurposing for novel coronavirus 2019-NCoV/SARS-CoV-2</article-title>. <source><italic toggle="yes">Cell Discovery</italic></source>, (<issue>1</issue>), <fpage>14</fpage> . <pub-id pub-id-type="doi">10.1038/s41421-020-0153-3</pub-id><pub-id pub-id-type="pmid">32194980</pub-id></mixed-citation></ref></ref-list><glossary><def-list><title>Abbreviations</title><def-item><term>Abbot bioavailability score</term><def><p>(ABS), predicts the probability of a compound to have &#x0003e; 10% oral bioavailability in a rat model; ADME is an abbreviation in pharmacokinetics and pharmacology for &#x02018;absorption, distribution, metabolism, and excretion&#x02019;, used to describes the disposition of a pharmaceutical compound within an organism</p></def></def-item><def-item><term>ADME</term><def><p>is an abbreviation in pharmacokinetics and pharmacology for &#x02018;absorption, distribution, metabolism, and excretion&#x02019;, used to describes the disposition of a pharmaceutical compound within an organism</p></def></def-item><def-item><term>COVID-19</term><def><p>Coronavirus disease 2019</p></def></def-item><def-item><term>main protease (M<sup>pro</sup>)</term><def><p>a cysteine protease, the main target for antiviral drugs against SARS and other coronavirus infections</p></def></def-item><def-item><term>Angiotensin-Converting Enzyme 2 (ACE2</term><def><p>a type I transmembrane metallocarboxypeptidase utilized by SARS-CoV-2 as a cellular entry receptor</p></def></def-item><def-item><term>MM-GBSA</term><def><p>molecular mechanics energies combined with generalized born and surface area, to enhance the binding affinity predictions</p></def></def-item><def-item><term>MM-GBSA</term><def><p>molecular mechanics energies combined with generalized born and surface area, to enhance the binding affinity predictions</p></def></def-item><def-item><term>severe acute respiratory syndrome corona virus-2 (SARS-CoV-2)</term><def><p>virus that cause COVID-19 disease</p></def></def-item><def-item><term>Swiss ADME</term><def><p>a tool to predict ADME parameters, pharmacokinetic properties, drug like nature.</p></def></def-item></def-list></glossary></back></article>